Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

FRANKFURT, Germany , Aug. 8, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical.

The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole b

See Full Page